Allarity Therapeutics Signs First CLIA Lab Services Contract; Shares Close Down 3.44%

Allarity Therapeutics (ALLR) announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy, an initial step toward building recurring revenue streams. The stock closed Thursday at $0.89, down 3.44%, and was at $0.89, up 0.39%, in pre-market trading. Under the agreement, Allarity will provide development, validation and related laboratory services to a European biotechnology company supporting the U.S. implementation of its precision oncology predictive device. Successful completion could lead to ongoing commercial testing and additional CLIA-related service revenue. The deal follows CLIA certification of Allarity's Hørsholm, Denmark laboratory in July 2026, which initially supported internal biomarker testing for its stenoparib program and Drug Response Predictor companion diagnostic strategy. Allarity said stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor in Phase 2 studies for ovarian cancer and relapsed small cell lung cancer, remains its top development priority.